Huang Hong-Yuan
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taipei, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Chang Gung Med J. 2008 Sep-Oct;31(5):431-40.
Endometriosis is a common, benign and chronic gynecological disorder. It is also an estrogen-dependent disorder that can result in substantial morbidity, including pelvic pain, pro gressive dysmenorrhea, dyspareunia, infertility and repeat surgeries. Endometriosis is often treated surgically upon diag nosis but with a higher rate of recurrence, suggesting that a combination of surgical and medical management might provide better outcomes. The primary goal of medical treatment for endometriosis is to halt the growth and activity of endometriosis lesions. The most widely utilized medical treat ment for endometriosis involves use of gonadotropin-releasing hormone (GnRH) agonists and oral contraceptives. Conventional agents also include androgen derivates and progestins. Due to the chronic nature of this disease, long-term or Dr. Hong-Yuan Huang repeated courses of medication may be required to control its related symptoms. Increasing knowledge about the pathogenesis of endometriosis at the cellular and molecular levels may give us the opportunity to use new, specific agents for treatment, including aromatase inhibitors, progesterone antagonists, selective progesterone receptor modulators, GnRH antagonists, intrauterine releasing systems with progestin and new pharmaceutical agents affecting inflammation, angiogenesis, and matrix metalloproteinase activity. Many of these promising new agents may prevent or inhibit the development of endometriosis. Further clinical trials may determine if these new therapies are superior to current medical treatment strategies for endometriosis.
子宫内膜异位症是一种常见的良性慢性妇科疾病。它也是一种雌激素依赖性疾病,可导致严重的发病率,包括盆腔疼痛、进行性痛经、性交困难、不孕和反复手术。子宫内膜异位症通常在诊断后进行手术治疗,但复发率较高,这表明手术和药物联合治疗可能会带来更好的效果。子宫内膜异位症药物治疗的主要目标是阻止子宫内膜异位症病灶的生长和活动。治疗子宫内膜异位症最广泛使用的药物包括促性腺激素释放激素(GnRH)激动剂和口服避孕药。传统药物还包括雄激素衍生物和孕激素。由于这种疾病的慢性性质,可能需要长期或反复用药来控制其相关症状。在细胞和分子水平上对子宫内膜异位症发病机制的认识不断增加,可能使我们有机会使用新的特异性药物进行治疗,包括芳香化酶抑制剂、孕酮拮抗剂、选择性孕酮受体调节剂、GnRH拮抗剂、含孕激素的宫内释放系统以及影响炎症、血管生成和基质金属蛋白酶活性的新型药物。许多这些有前景的新药可能预防或抑制子宫内膜异位症的发展。进一步的临床试验可能会确定这些新疗法是否优于目前治疗子宫内膜异位症的药物治疗策略。